PDC*line Pharma welcomes Dr. Mondher Mahjoubi as chairman of its board of directors
PDC*line Pharma strengthens its board of directors with an
industry leader in the field of immuno-oncology
Liège, Belgium and Grenoble, France, June 25, 2020 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces that Dr. Mondher Mahjoubi has been named as an independent board member and chairman of the board of directors.
With more than 25 years of leadership experience and expertise in the biopharmaceutical industry, Dr. Majhoubi will play a critical role in helping guide PDC*line Pharma to become a leader in immuno-oncology vaccines.
Currently, Dr. Mahjoubi is the chief executive officer and chairman of the executive board at Innate Pharma. Prior to joining Innate, Dr. Mahjoubi led AstraZeneca’s oncology therapy area franchise, playing an instrumental role in driving its oncology strategy. He also served as the senior vice president of global product strategy at Genentech; before that, he held marketing and medical affairs roles at Roche, Mayne Pharma, Sanofi-Aventis and Rhone Poulenc Rorer.
Dr. Mahjoubi is a medical oncologist trained at the Institut Gustave Roussy (Paris-Villejuif). He holds an M.D. from the University of Tunis and certifications in medical oncology from the University of Tunis and University of Paris Sud, as well as in clinical research and methodology from the University of Lariboisiere-Saint Louis.
“We are delighted to welcome Dr. Mahjoubi to our board of directors during this exciting stage in our company’s growth,” said Eric Halioua, CEO of PDC*line Pharma. “Mondher’s extensive leadership experience in the biopharmaceutical sector, coupled with his in-depth oncology and medical affairs expertise, will be a tremendous asset as we work to build a world-class biotech company in the field of immuno-oncology.”
“With decades of leadership experience in those key areas that are so important to our future strategy, including oncology drug development and portfolio strategy, we are extremely pleased that Mondher is taking the responsible role of chairman of the board,” said François Fontaine, board member of PDC*line Pharma and investment manager at SFPI-FPIM.
“I’m passionate about advancing great science. The PDC*line Pharma team has developed an innovative oncology platform with potential for treating a wide range of cancers,” said Dr. Mondher Mahjoubi. “I look forward to working with the team and helping the organization position itself for long-term success.”
See below links to the full Press Release in English and French: